Startup Gero raised investment to stop the ageing process
Biotech company received $6 million to prevent ageing
Gero, the Russian-Singaporean biotech startup, has successfully secured $6 million in funding from investors, including venture capital firm Melnichek Investments, the VitaDAO organisation, and Leonid Lozner, co-founder of the EPAM technology corporation.
The newly acquired funds will be utilised by Gero to delve into ageing processes, advance drug development targeting ageing, expand its scientific team, and enhance artificial intelligence-based platforms.
Maxim Kholin, co-founder of Gero, cited Nobel laureate physicist Richard Feynman’s perspective that ageing is not inherently inevitable, pointing out that certain organisms in nature do not experience ageing. He expressed the firm belief that Gero’s work could potentially halt the ageing process, highlighting the company’s significant progress in fundamental research.
Gero leverages AI technologies to uncover connections between various human diseases and the ageing process. The startup has also secured a patent for a platform exploring the impact of physics laws on biology. Since its establishment in 2015, Gero has garnered $5 million from investors and biotech firms.
In a recent development, Pfizer Corporation has entered into a partnership with Gero to harness machine learning technologies in identifying genes associated with fibrosing diseases.
